About Ubiquinone biosynthesis protein COQ9, mitochondrial
Ubiquinone biosynthesis protein COQ9, mitochondrial (COQ9) is a protein
from Homo sapiens identified by UniProt accession
O75208, 318 residues long.
MolForge cross-references it against 0 known binders and
52 disease associations.
Target properties
| Protein name | Ubiquinone biosynthesis protein COQ9, mitochondrial |
| UniProt accession | O75208 |
| Gene | COQ9 |
| Organism | Homo sapiens |
| Length | 318 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (52)
Diseases linked to this target (Open Targets).
- Encephalopathy - hypertrophic cardiomyopathy - renal tubular disease · score 0.73
- encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome · score 0.67
- coenzyme Q10 deficiency · score 0.65
- genetic disorder · score 0.41
- mitochondrial disease · score 0.37
- eosinophil count · score 0.12
- eosinophil percentage of leukocytes · score 0.05
- CCL17 measurement · score 0.04
- CX3CL1 measurement · score 0.04
- familial infantile bilateral striatal necrosis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75208-F1 | alphafold | PREDICTED | 77.60 | — |
Amino-acid sequence (318 residues)
MAAAAVSGAL GRAGWRLLQL RCLPVARCRQ ALVPRAFHAS AVGLRSSDEQ KQQPPNSFSQ QHSETQGAEK PDPESSHSPP RYTDQGGEEE EDYESEEQLQ HRILTAALEF VPAHGWTAEA IAEGAQSLGL SSAAASMFGK DGSELILHFV TQCNTRLTRV LEEEQKLVQL GQAEKRKTDQ FLRDAVETRL RMLIPYIEHW PRALSILMLP HNIPSSLSLL TSMVDDMWHY AGDQSTDFNW YTRRAMLAAI YNTTELVMMQ DSSPDFEDTW RFLENRVNDA MNMGHTAKQV KSTGEALVQG LMGAAVTLKN LTGLNQRR
Explore Ubiquinone biosynthesis protein COQ9, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets